clinical trial · NCT07400458
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration
Pharmicell Co., Ltd.·N/A·recruiting·n = 100
Acute Myocardial InfarctionHearticellgram-AMI
brief summary
This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
started
Mar 3, 2022
primary completion
Oct 12, 2028
completion
Sep 30, 2032
last updated
Feb 10, 2026
detailed description
To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.
official title
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol